Skip to Content
  • 1.8
    CiteScore
  • 24 days
    Submission to First Decision
  • 7 days
    Acceptance to Publication

Allergies

Allergies is an international, peer-reviewed, open access journal on allergy and immunology published quarterly online by MDPI.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High Visibility: indexed within Scopus, Embase, and other databases.
  • Journal Rank: CiteScore - Q2 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous)).
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 23.4 days after submission; acceptance to publication is undertaken in 6.3 days (median values for papers published in this journal in the first half of 2026).
  • Recognition of Reviewers: Reviewers whose reports are timely and of high quality receive an APC discount voucher for a future publication in an MDPI journal. Become a reviewer.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (157)

  • Article
  • Open Access

Atopic dermatitis (AD) is a prevalent pediatric inflammatory skin disorder. While AD prevalence has stabilized in high-income nations, it is rising rapidly in low-and middle-income countries due to urbanization and changing environmental factors. This study investigates AD prevalence and associated socio-demographic, environmental, and dietary factors among preschool children in Alexandra, an informal urban settlement in South Africa. A community-based, cross-sectional study was conducted among 3265 children under five years enrolled in early childhood development centers. Data were collected via parent-administered questionnaires using standardized International Study of Asthma and Allergies in Childhood criteria to assess AD status, along with socio-demographic, indoor/outdoor environmental, and dietary variables. Multivariate logistic regression determined adjusted odds ratios (AORs) for factors associated with AD. AD prevalence was 19.72%. Children aged 1 to 3 years (AOR = 2.24), those with a familial predisposition to asthma (AOR = 2.58), and those with a personal history of asthma (AOR = 3.62) had significantly higher odds of AD. Regarding environmental exposures, residing within 1 km of open sewage drastically increased AD odds (AOR = 3.61), as did exposure to indoor cats (AOR = 1.26) and dogs (AOR = 1.45). Conversely, using clean energy for cooking was strongly inversely associated with AD (AOR = 0.48). Dietary analysis revealed that high-frequency consumption of street vegetables (AOR = 2.19) and nuts (AOR = 1.36) was associated with increased AD odds, whereas frequent red meat (AOR = 0.52) and egg (AOR = 0.66) consumption showed protective associations. Pediatric AD is a significant public health burden in South African townships, heavily influenced by localized socio-ecological factors. Proximity to open sewage and reliance on dirty domestic fuels are major environmental correlates, while distinct, age-stratified dietary associations highlight the complex interplay of metabolic immaturity and urban environmental toxicity, underscoring the inadequacy of extrapolating HICs data to the settings of low-and middle-income countries. Future public health interventions must prioritize clean energy transitions and wastewater management to mitigate this growing burden.

Allergies

16 November 2026

Simulated conceptual framework of pediatric AD pathobiology and urban exposome.
  • Review
  • Open Access

Lichen sclerosus (LS) is a chronic immune-mediated and fibrosing mucocutaneous disorder with a multifactorial pathogenesis. Although autoimmune mechanisms and genetic susceptibility are well recognized, the contribution of exogenous triggers and contact allergens remains debated. This narrative review critically evaluates whether irritants, allergens, mechanical trauma, microbial dysbiosis, and infectious agents should be interpreted as primary etiological factors or as secondary disease modifiers in LS. A literature search was conducted in PubMed, Scopus, and Web of Science from database inception to June 2026, focusing on studies addressing epithelial barrier dysfunction, Koebnerization, contact dermatitis, patch testing, microbiome alterations, infectious triggers, immune pathways, and clinical management. Current evidence suggests that barrier dysfunction and cutaneous fragility may create a permissive microenvironment in which mechanical stress, irritants, contact allergens, repeated topical exposure, and microbial alterations can amplify inflammation and symptoms. Patch-testing studies support the clinical relevance of allergic contact dermatitis in selected patients with persistent or treatment-refractory symptoms, but do not establish contact allergy as a primary cause of LS. Similarly, microbiome and infectious data remain associative rather than causal. Overall, exogenous factors in LS are neither a complete myth nor a primary explanation for the disease; their relevance lies mainly in disease modulation and personalized management in selected patients.

Allergies

13 November 2026

Multilevel model of evidence in lichen sclerosus pathogenesis. Evidence is stratified according to the degree of direct support in LS. LS-specific evidence includes a predominantly Th1/cytotoxic immune profile and miR-155 upregulation [42], increased IL-17 and S100A7/psoriasin expression [43], TGF-β-associated fibroblast activation [48], and tissue/omics evidence of immune–stromal remodeling [49]. Clinical or associative evidence includes preliminary observations involving Th2/type 2 pathways [44,45], immune checkpoint alterations in pediatric LS [47], microbiome alterations [33,35,36,37,38,39,40,41], and coexisting contact sensitization [12,19,20,25,26]. Proposed or indirect mechanisms include mechanical stress and trauma [14,15,16], irritant and allergen exposure [10,12,18,19,20,21,22,25,26], infectious agents [34], and genetic/epigenetic susceptibility [6,49]. Arrows represent proposed biological or clinical interactions and should not be interpreted as demonstrating causal relationships. The relative contribution of these pathways may vary among patients.
  • Review
  • Open Access

Ocular allergy comprises a range of inflammatory conditions affecting the ocular surface, with allergic conjunctivitis (AC) representing a common clinical manifestation. Despite the availability of several therapeutic options, effective long-term management remains challenging because of the heterogeneous clinical presentation and complex underlying mechanisms of the disease. This narrative review summarizes the etiology, clinical manifestations, immunopathogenesis, and current and emerging therapeutic strategies for AC, emphasizing their clinical relevance and implications for disease management. Mild disease is generally managed with allergen avoidance, supportive measures, and topical antihistamines or dual-action agents, whereas severe or persistent disease may require topical corticosteroids or immunomodulators, depending on the phenotype and severity. Allergen-specific immunotherapy (AIT) may provide longer-term disease modification in selected patients. Emerging therapies, including biologics and targeted small-molecule inhibitors, offer additional treatment possibilities; however, clinical evidence for most remains limited, and further studies are needed to establish their efficacy, safety, and appropriate use. Important challenges include disease heterogeneity, limited availability of validated biomarkers, and difficulties translating experimental findings into clinical practice. Ultimately, treatment tailored to disease phenotype and severity, based on the underlying inflammatory mechanisms, can improve long-term disease control and ocular-surface outcomes. Continued research into the biological complexity of AC is essential for developing safer and more effective treatments that improve ocular health and quality of life.

Allergies

10 November 2026

Integrated immunopathogenesis of AC. Schematic illustration of the three major stages of AC: allergen sensitization and IgE production, immediate mast-cell activation and degranulation, and late-phase Th2-mediated and eosinophilic inflammation. These processes lead to acute allergic symptoms, ocular-surface damage, and potentially chronic inflammation with repeated allergen exposure. Figure created using Microsoft PowerPoint for Microsoft 365 (Version 2601; Build 19628.20214).
  • Article
  • Open Access

Background/Objectives: Although cefazolin is the recommended antibiotic for surgical prophylaxis, patients with a penicillin allergy label (PAL) frequently receive second-line antibiotics due to misconceptions regarding β-lactam cross-reactivity. Despite robust evidence supporting risk-stratified cefazolin use, implementation remains inconsistent. We evaluated the effect of a behaviour-informed, multidisciplinary implementation strategy on appropriate cefazolin utilisation among PAL patients undergoing surgery. Methods: A before-and-after quality improvement study was conducted at Singapore General Hospital. Following revision of the institutional surgical prophylaxis guidelines, a hospital-wide implementation strategy informed by the Capability–Opportunity–Motivation Behaviour (COM-B) framework was implemented through clinician education, workflow redesign, point-of-care prescribing prompts, multidisciplinary governance and organisational endorsement. The primary outcome was the median weekly proportion of eligible PAL patients receiving cefazolin. Secondary outcomes included perioperative allergic reactions and surgical site infections (SSIs). Results: A total of 126 patients in the pre-intervention period and 133 patients in the post-intervention period were included. The median weekly proportion of PAL patients receiving cefazolin increased from 22% to 50% (p < 0.01), with sustained improvement throughout the intervention period. Three patients (2.3%) developed suspected allergic reactions following cefazolin administration; one reaction was mild (urticaria), one was moderate (rash and chest tightness without haemodynamic instability), and one was suspected anaphylaxis. Significantly, no cases resulted in intensive care admission or cancellation of surgery. No statistically significant difference in SSI incidence was detected between patients receiving cefazolin and those receiving alternative antibiotics (0/96 vs. 5/163, p = 0.161); however, the small number of events limits interpretation of this exploratory safety outcome. Conclusions: A behaviour-informed implementation strategy combining COM-B-guided intervention design, multidisciplinary governance and anaesthesiologist-led implementation was associated with a safe increase in cefazolin use for surgical prophylaxis in PAL patients. These findings suggest that interventions addressing behavioural and organisational barriers may support the implementation of evidence-based recommendations and improve cefazolin uptake in routine perioperative practice, although the impact on clinical outcomes requires further evaluation.

Allergies

10 November 2026

A systematic approach using the COM-B framework to increase the use of cefazolin surgical prophylaxis in patients with a penicillin allergy label.

Featured Articles of Last Quarter

Type 2 inflammatory pathways in severe pediatric asthma and mechanisms of action of currently approved biologic therapies. Environmental triggers, including allergens, respiratory viruses, and air pollution, activate the airway epithelium, leading to the release of the epithelial-derived alarmins thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25. These mediators activate dendritic cells and type 2 innate lymphoid cells (ILC2s), promoting T helper 2 (Th2) polarization and the downstream production of IL-4, IL-5, and IL-13. IL-4 stimulates B-cell class switching and immunoglobulin E (IgE) production, while IL-5 promotes eosinophil maturation, recruitment, and survival through binding to the IL-5 receptor α (IL-5Rα) on eosinophils. Tezepelumab blocks TSLP upstream of the type 2 inflammatory cascade; omalizumab binds circulating IgE, preventing its interaction with FcεRI; mepolizumab neutralizes IL-5; benralizumab targets IL-5Rα, leading to eosinophil depletion; and dupilumab inhibits IL-4 receptor α (IL-4Rα), thereby blocking both IL-4- and IL-13-mediated signaling. Together, these targeted therapies reduce type 2 inflammation, decrease asthma exacerbations, and improve disease control. Created with the assistance of ChatGPT (GPT-5.5; OpenAI), under the authors’ supervision.
PRISMA flow diagram of study selection for inclusion in the systematic review.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Allergies - ISSN 2313-5786